Johnson & Johnson Impact Ventures

Johnson & Johnson is a global leader in healthcare, focusing on the research, development, manufacturing, and sale of a diverse range of products that include pharmaceuticals, medical devices, and diagnostics. The company is dedicated to improving access to healthcare and fostering healthier communities. In addition to its core business, Johnson & Johnson also engages in initiatives that support purpose-driven entrepreneurs who are innovating at the forefront of care, demonstrating its commitment to advancing health and well-being on a broader scale.

William Cohn

VP, Medical Device Companies, Johnson and Johnson

Alex Gorsky

Chairman and CEO

Neville L. Johnson

Partner

Hirak Parikh

Associate, Venture Investments

Sandra Peterson

Group Worldwide Chairman

Tim Schmid

Executive Vice President, Worldwide Chairman, MedTech

85 past transactions

CareLoop Health

Seed Round in 2025
CareLoop, an innovation emerging from the University of Manchester, furnishes patients with digital support resources while simultaneously providing healthcare professionals with the means to monitor and track patient symptoms.

Intra-Cellular Therapies

Acquisition in 2025
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on developing innovative treatments for neuropsychiatric and neurologic diseases, as well as other disorders affecting the central nervous system (CNS) in the United States. The company’s lead drug candidate, CAPLYTA, targets schizophrenia, bipolar disorder, and behavioral disturbances associated with dementia and autism. In addition to CAPLYTA, the company is advancing several other candidates, including ITI-002, which inhibits phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, aimed at substance use disorders and related psychiatric conditions such as depression and anxiety. Intra-Cellular Therapies also utilizes its CNSProfile technology platform to generate molecular signatures for drug compounds, enhancing insights into the actions of CNS drugs and aiding in drug discovery. The company is headquartered in New York, New York.

Alessa Therapeutics

Seed Round in 2024
Alessa Therapeutics, Inc. is a pre-clinical stage company based in San Francisco, California, focused on developing localized treatments for solid organ diseases, particularly prostate cancer. Founded in 2018, the company specializes in a drug delivery implantable system that administers anti-androgen drugs directly to prostate tumors. This innovative system allows for sustained and localized treatment, minimizing systemic exposure and enhancing the efficacy of therapy for patients. By concentrating on specific organ diseases, Alessa Therapeutics aims to improve treatment outcomes and quality of life for patients suffering from these conditions.

Tempo Therapeutics

Venture Round in 2024
Tempo Therapeutics is a life science company focused on advancing regenerative medicine through innovative materials that are immune stealth and minimally invasive. The company harnesses immunomodulation and material science to create cell-free synthetic hydrogels designed to unlock the body's natural regenerative capabilities. By employing geometric technology, these materials can effectively control inflammation and promote accelerated healing rates. Tempo Therapeutics aims to transform medical technology by developing synthetic tissue hybrids applicable to various bodily tissues, including skin, bone, heart, and brain, while minimizing the risk of immune rejection commonly associated with traditional approaches.

V-Wave

Acquisition in 2024
V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Yellow Jersey Therapeutics

Acquisition in 2024
Yellow Jersey Therapeutics provides pharmaceutical therapeutic and medical services.

Proteologix

Acquisition in 2024
Proteologix is a precision immunology company powered by proprietary multi-specific antibody technologies. The company is dedicated to the discovery and development of safe and convenient therapeutics that target multiple disease-driving pathways to potentially deliver high-bar efficacy for patients with immune-mediated diseases.

Hamilton Health Box

Series A in 2024
Hamilton Health Box operates onsite direct primary and urgent care microclinics tailored for self-insured employers. The company focuses on making healthcare accessible, convenient, and affordable, ensuring that care is delivered when and where it is needed. Hamilton Health Box employs a hybrid primary care model that caters to small employers and rural populations, fostering healthier communities while aiming to reduce overall healthcare costs. With a dedicated team of healthcare professionals, the company provides comprehensive care for employees and their families, acting as a reliable partner in managing their health needs.

Johnson & Johnson Impact Ventures

Acquisition in 2024
Johnson & Johnson is a global leader in healthcare, focusing on the research, development, manufacturing, and sale of a diverse range of products that include pharmaceuticals, medical devices, and diagnostics. The company is dedicated to improving access to healthcare and fostering healthier communities. In addition to its core business, Johnson & Johnson also engages in initiatives that support purpose-driven entrepreneurs who are innovating at the forefront of care, demonstrating its commitment to advancing health and well-being on a broader scale.

Health In Her HUE

Seed Round in 2024
Health In Her HUE is a digital platform aimed at connecting Black women and women of color with culturally sensitive healthcare providers. The platform offers access to evidence-based health content that resonates with the cultural experiences of these communities. By leveraging technology, media, and community support, Health In Her HUE seeks to address and reduce racial health disparities, ultimately improving health outcomes for Black women. It provides a space for these women to comfortably engage with healthcare providers and fosters better communication within their communities regarding health matters.

Ambrx

Acquisition in 2024
Ambrx, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, that specializes in the development of engineered precision biologics using an advanced genetic code technology platform. This innovative approach enables the incorporation of synthetic amino acids into proteins, leading to the creation of next-generation therapeutics, including antibody drug conjugates (ADCs), bispecific antibodies, and long-acting therapeutic peptides. Ambrx's development pipeline features several product candidates, such as ARX788, ARX517, and ARX305, which target various therapeutic areas, including oncology, metabolic, and cardiovascular diseases. The company collaborates with organizations like MabSpace Biosciences, BeiGene, and NovoCodex Biopharmaceuticals to enhance its research and development efforts. Founded in 2003, Ambrx aims to optimize the efficacy, safety, and usability of its biopharmaceutical products.

54 Collective

Venture Round in 2023
54 Collective is a venture capital firm based in Johannesburg, South Africa, founded in 2018. The company focuses on building and scaling African tech startups by providing catalytic capital and tailored support to entrepreneurs. It invests primarily in sectors such as fintech, health tech, agritech, logistics, and e-commerce. By integrating impact into its investment strategy, 54 Collective aims to deliver financial returns to investors while facilitating the growth of innovative businesses. The firm leverages its extensive global network to offer additional resources and support, helping founders navigate challenges and scale their ventures effectively.

Mamotest

Seed Round in 2023
Mamotest is a company focused on improving breast cancer outcomes through a digital platform that leverages artificial intelligence. By democratizing access to early diagnosis and patient guidance, Mamotest aims to transform the care delivery process. The platform employs telediagnosis and ensures complete traceability of the patient journey, promoting a proactive approach to health rather than a reactive one. Operating in Spain, Argentina, and Mexico, Mamotest's mission is to significantly reduce breast cancer mortality rates.

SwipeRx

Series B in 2023
SwipeRx is a digital platform designed to enhance the operations of pharmacies by connecting pharmaceutical manufacturers, pharmacies, and patients. It offers a range of services, including specialized healthcare logistics, negotiated pricing, and financing solutions, creating a robust network for pharmacy purchasing. The platform generates insights that facilitate collaboration with pharmacies, improve pharmacist education, and strengthen market access. Additionally, it optimizes commercial strategies and enhances daily operational efficiencies. By providing real-time access to patient and sell-out data, SwipeRx enables its clients to improve patient affordability, access, and adherence to medications.

Abiomed

Acquisition in 2022
Abiomed is a company that specializes in mechanical circulatory support devices aimed at assisting heart failure patients. It develops, manufactures, and markets products designed to improve blood flow and temporarily aid the heart's pumping function, allowing the organ to rest, heal, and recover. Its devices are primarily utilized in cardiac catheterization labs by interventional cardiologists and in surgical settings by heart surgeons. These products are essential for patients requiring hemodynamic support before, during, or after procedures such as angioplasty and heart surgery. A significant portion of Abiomed's revenue is generated from its Impella product portfolio, which includes advanced percutaneous micro heart pumps equipped with integration motors and sensors.

SwipeRx

Series B in 2022
SwipeRx is a digital platform designed to enhance the operations of pharmacies by connecting pharmaceutical manufacturers, pharmacies, and patients. It offers a range of services, including specialized healthcare logistics, negotiated pricing, and financing solutions, creating a robust network for pharmacy purchasing. The platform generates insights that facilitate collaboration with pharmacies, improve pharmacist education, and strengthen market access. Additionally, it optimizes commercial strategies and enhances daily operational efficiencies. By providing real-time access to patient and sell-out data, SwipeRx enables its clients to improve patient affordability, access, and adherence to medications.

IndyGeneUS AI

Grant in 2021
IndyGeneUS AI is a Black-Owned and Service-Disabled Veteran-Owned Small Business specializing in genomics. The company is developing the world's largest blockchain-encrypted repository of clinical and genomic data specifically for indigenous and diasporic African populations. Utilizing proprietary technology, IndyGeneUS AI integrates multi-omics data, electronic healthcare records, and scientific literature to identify novel signature sequences, biomarkers, and polygenic risk scores. This extensive data repository aims to enhance disease prevention, detection, and drug discovery while promoting clinical disease management and precision health equity. By focusing on the unique genomic characteristics of these populations, the company seeks to improve the efficiency and quality of healthcare delivery.

Lucia Health Guidelines

Grant in 2021
Lucia Health Guidelines develops a clinical decision support tool that utilizes cloud computing and machine learning to enhance adherence to clinical guidelines at the point of care. The primary focus of the company's platform is to improve the diagnosis and treatment of Atrial Fibrillation (AFib) within Emergency Departments. By providing clinicians with effective tools to accurately identify AFib, the technology facilitates the initiation of guideline-recommended treatments aimed at preventing strokes. This approach not only aims to save lives and improve patient outcomes but also seeks to lower overall healthcare costs by promoting adherence to established medical recommendations.

Radical Health

Seed Round in 2021
Radical Health is a healthcare technology company focused on promoting health equity through meaningful conversations and community engagement. By leveraging AI-enabled technology, Radical Health helps individuals better understand their health during medical visits, fostering trust and self-advocacy. The company offers workshops and training that facilitate deeper discussions around the social determinants of health for both community members and healthcare providers. In addition, Radical Health features Radical Relay, an AI-based chat application designed to empower individuals with knowledge of their rights throughout pregnancy. Through its innovative approach, Radical Health aims to equip and empower people to actively advocate for themselves within the healthcare system.

TQIntelligence

Venture Round in 2021
TQIntelligence, Inc. operates a platform that measures emotional distress severity through voice-based artificial intelligence technology. Founded in 2016 and headquartered in Atlanta, Georgia, the company integrates various data sources to provide cognitive insights into risk stratification, treatment outcomes, and personalized behavioral health interventions. Its key products include TQ-Intelligence, which utilizes voice and speech analytics alongside psychometrically sound instruments, and TQ Analytics, which leverages existing electronic medical record data to deliver actionable insights. TQIntelligence's machine learning analytics and real-time prediction capabilities support therapists in diagnosing mental health issues, particularly for children and adolescents, including those from BIPOC and LGBTQ communities. By focusing on voice biomarkers, the company aims to enhance treatment planning and reduce care costs while improving outcomes in the behavioral healthcare sector.

Ayana Therapy

Seed Round in 2021
Ayana Therapy is a telehealth platform dedicated to providing mental health services to marginalized communities, including people of color and LGBTQ+ individuals. It utilizes a smart matchmaking algorithm to connect users with licensed therapists who are compatible based on cultural experiences and identity traits such as race, gender identity, class, sexuality, and ethnicity. By offering virtual communication options, Ayana Therapy aims to address significant barriers to mental health care, including high costs, stigma, and a lack of cultural competency within the healthcare system. The platform seeks to create a safe space for those whose voices have been historically dismissed or neglected, facilitating access to essential mental health support.

Patient Orator

Seed Round in 2021
Patient Orator is a mental health company that focuses on enhancing communication between marginalized communities and healthcare providers through its mobile application. The platform utilizes storytelling to create a safe digital environment where users can openly discuss their health concerns and social needs without fear of judgment or bias. By emphasizing preventative medicine and shared decision-making, Patient Orator aims to improve patient experiences and overall population health. The application is designed to ensure that individuals from diverse backgrounds, regardless of race, ethnicity, gender, nationality, or insurance status, have better access to essential healthcare resources.

Momenta Pharmaceuticals

Acquisition in 2020
Momenta Pharmaceuticals, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, that focuses on the discovery and development of innovative therapeutics for rare immune-mediated diseases. The company's product pipeline includes novel therapeutics such as M281, a fully-human monoclonal antibody targeting the neonatal Fc receptor to reduce circulating IgG antibodies; M254, aimed at treating inflammatory diseases; and M230, a recombinant trivalent IgG1 Fc multimer designed for enhanced therapeutic activity. Additionally, Momenta has developed complex generic products, including M-Enoxaparin, a generic version of Lovenox, and M356, a generic of Copaxone for multiple sclerosis. Momenta also has biosimilar programs, including M923, a biosimilar of HUMIRA, and M710, a biosimilar of EYLEA for various eye conditions. Despite previously pursuing the generics and biosimilars market, the company shifted its focus to innovative drug development, with several promising candidates in the pipeline for autoimmune diseases. Momenta was founded in 2001 and operates as a subsidiary of Johnson & Johnson.

TARIS Biomedical

Acquisition in 2019
TARIS Biomedical, Inc. is a therapeutically focused urology company based in Lexington, Massachusetts, established in 2008. The company specializes in developing innovative treatments for challenging bladder diseases, including bladder cancer and overactive bladder. TARIS's unique drug delivery system allows for the continuous release of medications within the bladder over extended periods, ranging from weeks to months. This system is designed to be deployed and retrieved through minimally invasive, in-office procedures, enabling a tailored approach to drug release that meets the specific needs of various bladder conditions. As of December 2019, TARIS Biomedical operates as a subsidiary of Janssen Research & Development, LLC.

Verb Surgical

Acquisition in 2019
Verb Surgical Inc. is a company that develops a digital surgery platform aimed at transforming surgical procedures. Established in 2015 and headquartered in Santa Clara, California, the company focuses on integrating robotics, advanced visualization, sophisticated instrumentation, data analytics, and connectivity to enhance the capabilities of operating room professionals. By leveraging these technologies, Verb Surgical seeks to improve patient outcomes and reduce the overall cost of care, making surgical procedures more accessible and efficient. As a subsidiary of Johnson & Johnson Innovation - JJDC, Inc., Verb Surgical aims to democratize surgery through its innovative platform.

knowRX Health

Pre Seed Round in 2019
KnowRX is a developer of a cloud-based digital healthcare platform designed to enhance therapeutic care by facilitating patient and physician engagement. The platform employs machine learning technology, known as Maestro ML™, to create personalized care pathways that support clinical trial participation, improve medication adherence, and promote daily wellness activities across nutritional, psychological, and physical domains. It provides healthcare providers and patients with critical drug information, current clinical trial updates, and resources for selecting appropriate therapies. Additionally, the platform offers access to counseling, genomic data for treatment compatibility, nutritional guidance, and instructional content on clinical research. By streamlining communication between patients and healthcare professionals, KnowRX aims to optimize treatment outcomes and empower patients in their self-care journeys.

M-Scan

Grant in 2019
M-Scan is a medical device company focused on developing portable mobile ultrasound devices specifically designed for pregnant mothers. The company aims to improve maternal and neonatal health by leveraging smart device technology to facilitate early detection and management of risks associated with maternal and neonatal mortality. By providing these innovative ultrasound solutions, M-Scan seeks to enhance the quality of life for mothers and their children, particularly in resource-limited settings where access to traditional healthcare may be challenging.

Uganics

Grant in 2019
Uganics is an organization providing organic mosquito repellent products including soaps, candles, lotion bars, and essential oils. Uganics produces an affordable and long-lasting organic mosquito repellent soap that helps mothers with children below the age of five in rural communities to prevent mosquito bites.

Tiny Hearts

Grant in 2019
Tiny Hearts provides production and deployment of phototherapy treatment essentials, procurement and supply of other medical equipment and disposables to hospitals. Their customers inquiries are addressed through phone, email, and online applications.

DayTwo

Series B in 2019
DayTwo Ltd. is a precision nutrition company headquartered in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome insights to improve health outcomes and prevent diseases such as diabetes, prediabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo employs microbiome sequencing to create personalized dietary recommendations, known as Food Prescriptions™, tailored to individual responses to food. This approach helps manage blood sugar levels, enhance energy, control hunger, and promote weight loss. DayTwo delivers its services through a digital platform and mobile application, enabling users to track their progress and communicate with certified diabetes care specialists and registered dietitians. By emphasizing personalized nutrition based on scientific research, DayTwo aims to empower patients to lead healthier lives through informed dietary choices.

Oncochain

Non Equity Assistance in 2019
Oncochain is focused on creating a real-world data platform tailored for oncology, aimed at standardizing and aggregating anonymized data from cancer patients. This platform generates valuable analytics that support pharmaceutical research and enhance value-based care for healthcare providers. Utilizing a web-based oncology-specific electronic health record, Oncochain develops operational data repositories that streamline the information flow between providers and enhance the skills of oncology professionals. The platform significantly aids research by reducing the time required for patient recruitment in clinical trials and establishing a framework for multi-centric study design and implementation. Through its SaaS analytics tool, Oncochain provides critical real-world data insights to clients, including pharmaceutical companies and contract research organizations, ultimately contributing to improved outcomes in oncological care and accelerating research efforts.

Auris Health

Acquisition in 2019
Auris Health, Inc. is a medical technology company based in Redwood City, California, that specializes in the development of robotic systems for diagnostic and therapeutic procedures. Founded in 2007, the company is known for its Monarch Platform, which enhances endoscopic procedures by utilizing flexible robotics, advanced imaging technology, and micro-instrumentation. This platform allows for minimally invasive access to the body through natural openings using small cameras and tools, thereby improving patient outcomes and potentially reducing healthcare costs. Additionally, Auris Health is working on a dual-arm microsurgical system designed for ophthalmic surgery, further expanding its focus on innovative robotic solutions for various medical applications. Auris Health operates as a subsidiary of Johnson & Johnson.

CI:Z Holdings

Acquisition in 2018
Ci:z Holdings Co., Ltd. is a Japan-based company engaged in the development, manufacturing, and sale of cosmetics, health foods, and beauty care products. Founded in 1999 and headquartered in Tokyo, the company operates primarily through two segments: cosmetics and health food. The cosmetics segment includes a diverse range of products designed for various skin issues, featuring brands such as Dr.Ci:Labo, Labo Labo, and Genomer, which contribute significantly to the company's revenue. The health food segment offers nutritional supplements and other products aimed at enhancing health and beauty from within. Ci:z Holdings distributes its products through mail order, wholesale channels, and directly operated stores, as well as through retail outlets such as drug stores and department stores, both in Japan and internationally.

Zarbee's

Acquisition in 2018
Zarbee's, Inc. specializes in the manufacture and sale of cough and throat relief products, immune support items, and vitamins and supplements for both children and adults. Founded in 2007 and headquartered in Draper, Utah, the company provides its products through various retail and online channels. Zarbee's is known for its commitment to natural health solutions and offers clinically proven health tips and advice for families. Additionally, it maintains a location in Greenwich, Connecticut. As of September 2018, Zarbee's operates as a subsidiary of Johnson & Johnson Consumer Inc.

Cue

Series B in 2018
Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

Dreem

Venture Round in 2018
Dreem is a neurotechnology company focused on enhancing human potential through innovative consumer technology. Its primary product is a wearable device that improves the quality of deep sleep by monitoring brainwaves and analyzing sleep patterns. The device employs sound stimulation to extend deep sleep duration, which can lead to improved daily performance. By utilizing machine learning algorithms, Dreem's headband provides real-time analysis of sleep stages and delivers personalized insights and tips that adapt based on individual sleeping habits. This approach aims to help users achieve faster sleep onset, longer deep sleep, and a refreshed awakening.

Orthotaxy

Acquisition in 2018
Orthotaxy is a medical technology company based in Gières, France, specializing in software-enabled surgery solutions for the healthcare industry. The company focuses on designing and developing computer-assisted platforms that enhance surgical procedures. With a team of qualified engineers, Orthotaxy creates innovative medical devices that are subject to rigorous quality assurance processes. This approach allows healthcare providers to personalize surgical procedures and optimize outcomes for patients.

Bloomlife

Grant in 2018
Bloomlife is a women's health company focused on addressing critical challenges in maternal health through an innovative remote care platform. By integrating connected devices with cloud-based data analytics, Bloomlife enhances access to care and empowers expectant mothers while providing clinicians with essential information to better screen and manage pregnancy complications. The company's prenatal wearable technology is designed to assess fetal health, enabling the identification of potential complications that could lead to serious outcomes such as brain damage or stillbirth. This approach marks a significant departure from traditional methods of managing high-risk pregnancies, which often involve frequent in-person appointments and lengthy referral processes. Bloomlife aims to be a leader in remote maternal care, facilitating timely interventions and support for women, regardless of geographic barriers.

Prapela

Grant in 2017
Prapela is a company that offers noninvasive stimulation therapy designed to enhance the health of newborns, specifically targeting issues such as irregular breathing and low oxygenation. By placing a reusable pad inside a hospital bassinet or incubator, Prapela provides gentle stimulation that supports the natural processes of breathing control and oxygenation. This therapy aims to improve cardiorespiratory outcomes while reducing the need for pharmacotherapy and minimizing the duration of conventional treatments for severe medical conditions. Since its inception, Prapela has garnered significant recognition as a leading pediatric medical device startup, receiving multiple awards and over $8 million in grants. The company collaborates with neonatologists, the National Institutes of Health, and the FDA to develop and refine its solutions, contributing to better health outcomes for newborns.

DayTwo

Series A in 2017
DayTwo Ltd. is a precision nutrition company headquartered in Tel Aviv-Yafo, Israel, that focuses on leveraging gut microbiome insights to improve health outcomes and prevent diseases such as diabetes, prediabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). Founded in 2015, DayTwo employs microbiome sequencing to create personalized dietary recommendations, known as Food Prescriptions™, tailored to individual responses to food. This approach helps manage blood sugar levels, enhance energy, control hunger, and promote weight loss. DayTwo delivers its services through a digital platform and mobile application, enabling users to track their progress and communicate with certified diabetes care specialists and registered dietitians. By emphasizing personalized nutrition based on scientific research, DayTwo aims to empower patients to lead healthier lives through informed dietary choices.

Actelion Pharmaceuticals

Acquisition in 2017
Actelion Ltd is a Swiss biopharmaceutical company dedicated to the discovery, development, and commercialization of low molecular weight drugs aimed at addressing various medical conditions. The company's primary focus is on pulmonary arterial hypertension (PAH), offering several treatments including Tracleer, Opsumit, Uptravi, Ventavis, and Veletri, each designed to target different stages of the disease through various administration methods. Additionally, Actelion markets Zavesca, an oral treatment for type 1 Gaucher disease, and Valchlor, which is indicated for a rare form of blood cancer. Established in 1997 and headquartered in Allschwil, Switzerland, Actelion has developed a robust global commercial infrastructure for its orphan drugs and actively enhances its product pipeline through in-licensing and acquisitions. The company also collaborates with Merck & Co., Inc. to explore new classes of renin inhibitors for cardio-renal diseases, reflecting its commitment to addressing a wide range of health challenges, including cardiovascular, immunological, infectious, metabolic, and central nervous system disorders.

RayIoT Solutions

Convertible Note in 2017
RayIoT Solutions Inc. specializes in developing innovative monitoring devices designed for health and safety. One of its flagship products, Raybaby, is a sophisticated baby monitor that tracks a child's respiration and sleep patterns, providing alerts for elevated respiratory rates that may indicate fever or other health issues. Equipped with an infrared video camera, Raybaby allows for live video streaming in complete darkness, along with built-in speakers and audio monitoring through a highly sensitive microphone. In addition, the company offers a wall-mounted monitoring device that transforms any space into a mini intensive care unit, continuously monitoring breathing rates and enabling the early detection of respiratory distress for patients in self-quarantine or quarantine facilities.

Neurotrack

Grant in 2016
Neurotrack is a digital health company focused on transforming the diagnosis and management of Alzheimer's and other dementias. Founded in 2012 by Elli Kaplan and neuroscientist Dr. Stuart Zola, the company is headquartered in Redwood City, California. Neurotrack develops user-friendly, clinically validated cognitive assessments that can be administered in clinical settings or at home, allowing for early detection of cognitive impairment and ongoing monitoring of cognitive function. The company's solutions are designed to fit seamlessly into various workflows, enabling healthcare providers to efficiently screen patients for cognitive decline and take necessary next steps. Neurotrack has published 27 peer-reviewed papers, holds 11 patents for its proprietary technology, and is registered as an FDA Class II medical device.

Abbott

Acquisition in 2016
Abbott is a global healthcare company focused on advancing health and well-being through a diverse array of products. The company manufactures and markets cardiovascular devices, diabetes management solutions, nutritional products for both adults and children, and diagnostic tools. Notable offerings include pacemakers, implantable cardioverter defibrillators, continuous glucose monitors, and a wide range of branded generic pharmaceuticals. Abbott is also a leader in molecular diagnostics, providing innovative technologies for disease diagnosis, therapy selection, and disease monitoring, with a strong portfolio of over 350 products. Headquartered in Mumbai, Abbott India Limited, a subsidiary of Abbott Laboratories, plays a significant role in providing high-quality medicines across various therapeutic areas such as women's health, cardiology, and gastroenterology. Approximately 60% of Abbott's sales come from international markets, reflecting its extensive global reach and commitment to enhancing health outcomes worldwide.

CI:Z Holdings

Post in 2016
Ci:z Holdings Co., Ltd. is a Japan-based company engaged in the development, manufacturing, and sale of cosmetics, health foods, and beauty care products. Founded in 1999 and headquartered in Tokyo, the company operates primarily through two segments: cosmetics and health food. The cosmetics segment includes a diverse range of products designed for various skin issues, featuring brands such as Dr.Ci:Labo, Labo Labo, and Genomer, which contribute significantly to the company's revenue. The health food segment offers nutritional supplements and other products aimed at enhancing health and beauty from within. Ci:z Holdings distributes its products through mail order, wholesale channels, and directly operated stores, as well as through retail outlets such as drug stores and department stores, both in Japan and internationally.

Vogue International

Acquisition in 2016
Vogue International LLC, headquartered in Clearwater, Florida, is a manufacturer and distributor of hair care and personal care products. Founded in 1987, the company offers a diverse range of products, including the FX™ line of hair styling items and the award-winning OGX® collection, which features shampoos, conditioners, and styling/treatment products. Vogue's products are designed with exotic ingredients and are free from harmful sulfates, appealing to a health-conscious consumer base. The company distributes its offerings through major retail channels, both in the United States and across 42 international markets. Vogue International is recognized for its commitment to innovation, sustainability, and delivering salon-quality products, maintaining a strong presence in the competitive beauty industry. As of 2016, Vogue operates as a subsidiary of Johnson & Johnson Consumer Inc.

Suncayr

Grant in 2016
Suncayr Inc., located in Mississauga, Canada, has developed an innovative colour-changing sticker called "SPOT" designed to enhance sun safety. This sticker is applied directly to the skin before sunscreen is used. While the sunscreen effectively blocks ultraviolet (UV) rays, the sticker remains clear; however, once the sunscreen's protective qualities diminish and UV exposure occurs, the sticker changes to purple. This simple yet effective tool provides users with clear visual feedback on their sunscreen's effectiveness, allowing families to enjoy outdoor activities with greater confidence in their sun protection.

TESARO

Post in 2016
Tesaro, Inc. is an oncology-focused biopharmaceutical company established in 2010 and headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing cancer therapeutics and supportive care products. Its primary offerings include ZEJULA, a potent oral poly polymerase inhibitor for the maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. Additionally, Tesaro is engaged in the development of several immunotherapy antibody candidates, including TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company collaborates with various organizations, such as AnaptysBio, Janssen Biotech, and Merck Sharp & Dohme, to enhance its research and development efforts. Tesaro aims to leverage its management team's expertise to identify and commercialize innovative treatments that improve the lives of cancer patients. As of January 2019, Tesaro operates as a subsidiary of GlaxoSmithKline.

Novira Therapeutics

Acquisition in 2015
Novira Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focused on discovering and developing antiviral drugs for chronic hepatitis B (HBV) and human immunodeficiency virus (HIV) infections. The company specializes in creating first-in-class oral therapeutics that target the capsid of these viruses, offering potential treatment options that address significant limitations in current therapies. Novira's innovative capsid inhibitors can be used alone or in conjunction with existing treatments, aiming to overcome challenges such as drug resistance and the need for lifelong therapy, particularly in chronic HBV infection, where existing polymerase inhibitors are rarely curative. Founded in 2006, Novira Therapeutics operates as a subsidiary of Johnson & Johnson, reflecting its strategic importance in addressing global health needs related to antiviral treatment.

NeoStrata Company

Acquisition in 2015
NeoStrata Company, Inc., based in Princeton, New Jersey, specializes in developing and marketing a diverse range of clinically-proven dermatological products. Founded in 1988 by Drs. Van Scott and Yu, the company is known for its pioneering work with alpha hydroxy acids (AHAs) and polyhydroxy acids, which enhance skin rejuvenation and address various skin conditions. NeoStrata's product offerings include anti-aging systems, treatment cosmetics for skin imperfections, topical solutions for conditions like psoriasis, and products targeting issues such as acne, hyperpigmentation, and severe dry skin. The company provides cleansers, moisturizers, serums, and specialized kits through multiple channels, including consumer outlets, dermatologists, spas, and beauty retailers worldwide. It operates as a subsidiary of Johnson & Johnson Consumer Inc.

Inter-Grosshandel GmbH

Non Equity Assistance in 2015
Inter-Grosshandel offers wide range of wholesale brand clothing

X01

Acquisition in 2015
U.K.-based cardiovascular drug startup

Jagdale industries

Acquisition in 2014
Jagdale Industries Pvt Ltd(JIPL) is a part of the well-established and one-of-the-oldest industrial family group of Bengaluru: ‘The Jagdale family’. The roots of Jagdale go back to 1939 when Associated Drugs Company Ltd., was set up and to the contributions of Late Shri. Radhakrishna Jagdale, founder Jagdale group. JIPL has pioneered several products including unique food, beverage, nutraceutical and pharmaceutical formulations, in line with the nation’s needs and market requirements.

Alios BioPharma

Acquisition in 2014
Alios BioPharma is focused on the discovery and development of innovative antiviral therapies aimed at treating both acute and chronic viral infections. The company employs a range of proprietary technologies, including small molecule activators that stimulate innate immunity, phosphate-protected nucleotide prodrug chemistry, and glycoprotein engineering of interferons. These complementary platforms enable the development of various therapeutic products targeting serious viral infections, such as chronic hepatitis B and C, HIV, respiratory viruses like pandemic influenza, and emerging viral diseases such as SARS. Alios BioPharma’s unique chemical library of nucleoside analogs and advanced virology-based screening systems further enhance its ability to create effective antiviral agents.

DePuy Synthes

Acquisition in 2014
DePuy Synthes is a leading manufacturer of orthopedic and medical technology equipment focused on enhancing patient recovery and mobility. The company produces a wide range of products designed for various specialties, including joint reconstruction, trauma, craniomaxillofacial surgery, spinal surgery, and sports medicine. Its offerings encompass surgical implants and biomaterials for fixation and orthopedic procedures, including systems for clavicle and olecranon plates, spinal solutions, and advanced surgical tools. Additionally, DePuy Synthes provides comprehensive services, such as advanced case management, loaner programs, and personalized solutions through its Trumatch platform. The company is dedicated to improving surgical outcomes and patient care through innovative products and services.

Aragon Pharmaceuticals

Acquisition in 2013
Aragon Pharmaceuticals is a discovery-stage small molecule company dedicated to developing therapeutics for hormone-resistant cancers, particularly focusing on prostate and breast cancer. The company specializes in anti-endocrine therapies that target the biology of these cancers. Its research emphasizes nuclear receptor biology, medicinal chemistry, and drug discovery, with the goal of identifying and developing selective androgen receptor degraders for prostate cancer and selective estrogen receptor degraders for estrogen-sensitive breast cancer.

Elsker

Acquisition in 2013
Elsker provides products to care for the skin health of babies. They provide body wash, shampoo, clothes, and talcum powder for babies. They also offer products for pregnant mothers.

Calibra Medical

Acquisition in 2012
Calibra Medical, Inc. develops medical devices and technologies in the diabetes sector. It offers insulin delivery devices. The company was formerly known as Seattle Medical Technologies, Inc. Calibra Medical, Inc. was founded in 2004 and is based in Redwood City, California.

SterilMed

Acquisition in 2011
SterilMed is a contracting manufacturer that specializes in the refurbishing and reprocessing of medical devices and equipment. The company offers services that include the repair and remanufacturing of a variety of medical instruments, such as flexible endoscope systems, power equipment, and surgical instrumentation. SterilMed caters to over 1,700 healthcare facilities across North America, providing essential support for the maintenance and sustainability of medical technologies.

Crucell

Acquisition in 2011
Crucell N.V. is a global biopharmaceutical company dedicated to the research, development, production, and marketing of vaccines, proteins, and antibodies aimed at preventing and treating infectious diseases. The company offers a diverse portfolio of vaccines, including those for hepatitis B, a fully-liquid vaccine for five key childhood diseases, and a virosome-adjuvanted vaccine for influenza. Additionally, Crucell markets travel vaccines, featuring the only oral anti-typhoid vaccine, an oral cholera vaccine, and the sole aluminum-free hepatitis A vaccine available. Its products are distributed in both public and private markets worldwide, reflecting its commitment to combating infectious diseases through innovative solutions.

Micrus Endovascular Corporation

Acquisition in 2010
Micrus Endovascular Corporation develops and manufactures both implantable and disposable medical devices used in the treatment of cerebral vascular diseases. Micrus Endovascular develops products that can be used by interventional neuroradiologists, interventional neurologists, and endovascularly trained neurosurgeons to treat both cerebral aneurysms responsible for hemorrhagic stroke and intracranial atherosclerosis, which may lead to ischemic stroke. The Micrus Endovascular product lines enable physicians to gain access to the brain in a minimally invasive manner through the vessels of the arterial system. It also sells stents, balloon catheters, access devices such as guide catheters, microcatheters, guidewires, and accessory products used in conjunction with its microcoils. Micrus Endovascular Corporation wasfounded in 1996 and is based in San Jose, California. As of September 27, 2010, Micrus Endovascular LLC operates as a subsidiary of Codman & Shurtleff, Inc.

Acclarent

Acquisition in 2009
Acclarent, Inc. is a medical device company focused on developing innovative technologies for ear, nose, and throat (ENT) patients. The company's primary emphasis is on balloon sinuplasty devices, which are minimally invasive tools designed to assist physicians in treating chronic sinusitis. These devices enable doctors to navigate the sinus anatomy and open blocked sinus ostia and passageways, facilitating sinus drainage. Acclarent's Balloon Sinuplasty technology and the Relieva product portfolio provide alternatives to conventional endoscopic surgical methods. The company received FDA clearances for its devices in 2005 and launched them commercially in the United States that same year, marking a significant advancement in sinus surgery.

Crucell

Post in 2009
Crucell N.V. is a global biopharmaceutical company dedicated to the research, development, production, and marketing of vaccines, proteins, and antibodies aimed at preventing and treating infectious diseases. The company offers a diverse portfolio of vaccines, including those for hepatitis B, a fully-liquid vaccine for five key childhood diseases, and a virosome-adjuvanted vaccine for influenza. Additionally, Crucell markets travel vaccines, featuring the only oral anti-typhoid vaccine, an oral cholera vaccine, and the sole aluminum-free hepatitis A vaccine available. Its products are distributed in both public and private markets worldwide, reflecting its commitment to combating infectious diseases through innovative solutions.

Cougar Biotechnology

Acquisition in 2009
Cougar Biotechnology, Inc

Omrix Biopharmaceuticals

Acquisition in 2008
Omrix Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets biological products for the biosurgical and immunotherapy markets.

HealthMedia

Acquisition in 2008
HealthMedia, founded in 1998 by Dr. Victor Strecher, specializes in scalable behavior change interventions aimed at health and wellness, disease management, and medication compliance. The company has developed innovative programs that replicate the benefits of health coaching sessions without the need for an actual coach. Its unique methodology and technology deliver effective outcomes similar to traditional health coaching while leveraging the scalability of web content. HealthMedia also creates specialized programs for pharmaceutical companies and medical device manufacturers, addressing a range of health issues, including drug and alcohol addiction, mental illness, and chronic conditions such as hypertension and heart disease.

Beijing Dabao Cosmetics

Acquisition in 2008
Beijing Dabao Cosmetics Co., Ltd. is a manufacturer based in Beijing, China, specializing in herbal cosmetic products. The company is involved in the development, production, sale, and export of a diverse range of items, including face wash, moisturizers, sunscreens, shampoos, and various other skincare products. Dabao aims to cater to both domestic and international markets, focusing on the growing demand for herbal and natural cosmetics.

Conor MedSystems

Acquisition in 2007
Conor MedSystems specializes in the development of controlled drug delivery technologies for vascular applications, primarily focusing on drug-eluting stents designed to treat coronary artery disease and restenosis. The company aims to enhance the effectiveness of vascular stents by incorporating mechanisms that allow for localized drug delivery to both coronary and peripheral vessels. Through its innovative approach, Conor MedSystems seeks to improve patient outcomes in the management of vascular conditions.

InnerPulse

Venture Round in 2007
InnerPulse, Inc. develops technology, devices, software protocols, and procedures to transform the treatment of cardiac arrhythmias. It offers invasive treatment that enables physicians to implant the life-saving Percutaneous Implantable Cardioverter Defibrillator within the patient's vascular system. InnerPulse, Inc. was formerly known as Interventional Rhythm Management, Inc.

CardioMEMS

Series D in 2006
CardioMEMS is a medical device company focused on the development and commercialization of proprietary wireless sensing and communication technology aimed at enhancing the management of severe chronic cardiovascular diseases, including heart failure, hypertension, and aneurysms. The company's innovative platform features miniature wireless sensors that can be implanted using minimally invasive techniques. These sensors transmit vital data, such as cardiac output, blood pressure, and heart rate, which are essential for effective patient management. By providing continuous monitoring, CardioMEMS' technology aims to improve patient outcomes and facilitate timely medical interventions.

Groupe Vendome SA

Acquisition in 2006
Groupe Vendome SA manufactures adult and baby skin care products.

Peninsula Pharmaceuticals

Acquisition in 2005
Peninsula Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the licensing, development, and commercialization of anti-infective therapies aimed at treating life-threatening infections in North America and Europe. The company's primary focus is on its lead product candidate, doripenem, a broad-spectrum antibiotic classified as a carbapenem. Currently, Peninsula is conducting six Phase III clinical trials for doripenem, which has also received Fast Track designation from the U.S. Food and Drug Administration for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia. The company was acquired by Johnson & Johnson, a global leader in healthcare products and services. As a privately held biopharmaceutical entity, Peninsula Pharmaceuticals concentrates on advancing antibiotics to address critical infection-related health challenges.

Transform Pharmaceuticals

Acquisition in 2005
Transform Pharmaceuticals was a pharmaceuticals company specializing in the discovery of improved formulations and novel crystalline forms of drug molecules. Transform’s product portfolio included Topiramate, an anti-epileptic drug. The company was acquired by Johnson & Johnson in 2005. The company was founded in 1998.

3-Dimensional Pharmaceuticals

Acquisition in 2003
3-Dimensional Pharmaceuticals is a drug discovery company that develops advanced technologies to enhance and expedite the drug discovery process. By integrating high-throughput screening, combinatorial chemistry, and structure-based design, the company leverages genome sequencing targets to create efficient and innovative drug discovery solutions.

Topspin Medical

Series B in 2002
TopSpin Medical has developed a groundbreaking technology for high-resolution MRI imaging using an IntraVascular MRI (IVMRI) catheter specifically designed for the coronary arteries. This innovative catheter eliminates the need for expensive and cumbersome external MRI setups by miniaturizing essential MRI components to less than 2 millimeters in size. The advanced technology allows for precise imaging within the coronary arteries, revolutionizing the field of medical imaging and providing a more efficient and cost-effective solution for clinicians and patients alike.

Tibotec

Acquisition in 2002
Tibotec is a biopharmaceutical company focused on developing anti-viral treatments, with several promising compounds in development for the treatment of infectious diseases including HIV.

LXN Corporation

Acquisition in 2001
LXN Corporation is a medical technology company that develops, manufactures, and markets products to help people with diabetes better manage their disease. The company offers GlucoProtein, a home-based test that measures overall glucose control. It allows patients and healthcare professionals to better monitor the overall effectiveness of diabetes treatments and make timely and effective therapy changes. LXN Corporation was founded in 1994 and is based in San Diego, California.

BabyCenter

Acquisition in 2001
BabyCenter is a digital parenting platform and subsidiary of Johnson & Johnson, dedicated to providing information and support for parents and parents-to-be throughout the journey of parenthood. The website offers resources on conception, pregnancy, childbirth, and early childhood, catering to the diverse needs of families. Alongside its companion site, ParentCenter, which focuses on children aged 2 to 8, BabyCenter helps users navigate parenting challenges with various tools, including pregnancy calendars, baby name finders, and due date calculators. The platform features buying guides and product comparisons to assist parents in making informed purchasing decisions, and it also includes an online store for direct merchandise purchases. Additionally, BabyCenter fosters a community atmosphere with bulletin boards, chat sessions, and Q&A features, allowing expectant mothers and new parents to connect with peers and medical professionals. Recognized for its excellence, BabyCenter won the Best Family and Parenting Site award at the 2006 Webby Awards.

SAND

Angel Round in 2000
SAND manufactures and sells financial POS machines.

Aveeno

Acquisition in 1999
Aveeno provides skin & hair care products made with the most effective ingredients.

MicroMass Communications

Venture Round in 1998
MicroMass Communications is a marketing agency specializing in healthcare communications, dedicated to applying evidence-based behavior change strategies to enhance patient health outcomes. Resulting from the merger of SPS and MicroMass, it has become one of the largest independent, full-service healthcare marketing and medical communications agencies in the Southeast. The agency offers a range of services, including patient engagement, relationship marketing, and health behavior consulting, primarily serving pharmaceutical, medical device, and biotechnology companies in the United States. With its unique expertise in human health behavior and healthcare professional advocacy, MicroMass is positioned to create effective, real-world solutions that drive meaningful improvements in patient care.

Gynecare

Acquisition in 1997
Gynecare offers an endometrial ablation system for the treatment of uterine disorders. Gynecare offers devices like ThermaChoice Uterine Balloon Therapy system for the treatment of women who experience dysfunctional uterine bleeding. It also offers a VersaPoint Bipolar Electrosurgery system to treat women diagnosed with benign uterine pathologies including fibroids, polyps, adhesions, and divided septa.

Mitek Products

Acquisition in 1995
Mitek Surgical Products provided bone anchors and minimally invasive surgical tools for orthopedic surgery. The company was founded by three Massachusetts Institute of Technology engineers in 1985.

Menlo Care

Acquisition in 1994
Menlo Care, Inc. manufactures and markets vascular access and urological devices.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.